首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1518459

重组蛋白市场规模 - 按产品和服务、应用、宿主细胞、最终用途和全球预测，2024 年 - 2032 年

Recombinant Proteins Market Size - By Products & Services, Application, Host-cell, End-use & Global Forecast, 2024 - 2032

出版日期: 2024年04月19日 | 出版商:

Global Market Insights Inc. | 英文 298 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在慢性病盛行率上升的推动下，重组蛋白市场收入在 2024 年至 2032 年期间将以超过 7.1% 的复合年增长率成长。 Physiopedia 报告称，全世界大约三分之一的成年人受到多种慢性病的影响。重组蛋白在开发生物製药和治疗这些复杂病症的标靶疗法中发挥着至关重要的作用。它们模仿天然蛋白质和选择性标靶疾病机制的能力使它们在创新疗法的开发中不可或缺。

此外，基因工程和蛋白质表现技术的进步使得能够更有效和精确地操纵遗传物质来产生所需的蛋白质。专注于加速新治疗和诊断产品的开发将提振未来几年的市场前景。

重组蛋白产业根据产品和服务、宿主细胞、最终用途和地区进行分类。

到 2032 年，酵母和真菌宿主细胞转译后修饰将快速增长。基于酵母的系统，包括酿酒酵母和毕赤酵母，由于其稳健性和与复杂蛋白质结构的兼容性而被广泛用于工业规模生产。黑曲菌和里氏木霉等真菌也越来越受到关注，特别是在酵素生产和工业生物技术应用领域。

到 2032 年，诊断领域将稳定成长，因为重组蛋白在检测疾病和监测患者健康的诊断分析中至关重要。它们用于生产对酶联免疫吸附测定 (ELISA)、侧流测定和分子诊断等诊断测试至关重要的抗原、抗体和酶。重组蛋白的特异性、敏感性和重现性使其成为开发准确可靠的诊断工具的理想选择。随着全球医疗保健产业强调早期疾病检测和个人化医疗，诊断中对重组蛋白的需求预计将会成长。

欧洲重组蛋白产业将在 2024 年和 2032 年出现良好的成长趋势，其特点是强大的生物製药产业、广泛的研究基础设施和支持性的监管框架。德国、瑞士和英国等国家是生物技术和药物研究的领先中心，推动了药物发现和开发中对重组蛋白的需求。此外，生物製药产品严格的品质标准和优惠的报销政策有助于市场扩张。

产业生态系统分析
产业影响力
- 成长动力
  - 对生物製药和治疗性蛋白质的需求不断增加
  - 蛋白质工程的进展
  - 慢性病和传染病的盛行率不断上升
- 产业陷阱与挑战
  - 生产成本高
  - 严格的监管要求
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品和服务分类，2021 - 2032 年

主要趋势
产品
- 细胞激素和生长因子
  - 干扰素 (IFN)
  - 白血球介素 (IL)
  - 其他细胞激素和生长因子
- 抗体
- 免疫检查点蛋白
- 病毒抗原
- 酵素
  - 激酶
  - 代谢酵素
  - 其他酵素
- 重组调节蛋白
- 荷尔蒙
- 其他产品
生产服务

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
药物发现与开发
- 生物製剂
- 疫苗
- 细胞和基因疗法
研究
诊断
其他应用

第 7 章：市场估计与预测：按宿主细胞，2021 - 2032

主要趋势
哺乳动物系统
昆虫细胞
酵母和真菌
细菌细胞
其他宿主细胞

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
製药和生物技术公司
学术及研究机构
合约研究组织 (CRO)
其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abcam Limited
Abnova Corporation
Bio-Rad Laboratories, Inc.
Enzo Life Sciences, Inc.
GenScript Biotech Corporation
Merck KGaA
Proteintech Group, Inc.
RayBiotech, Inc.
R&D Systems, Inc.
Sino Biological, Inc.
STEMCELL Technologies Inc.
Thermo Fisher Scientific Inc.

简介目录

Product Code: 9114

The Recombinant Proteins Market revenue will grow at over 7.1% CAGR during 2024-2032, driven by the rising prevalence of chronic diseases. Physiopedia reports that approximately one-third of adults worldwide are impacted by multiple chronic conditions. Recombinant proteins play a crucial role in developing biopharmaceuticals and targeted therapies for treating these complex conditions. Their ability to mimic natural proteins and selectively target disease mechanisms makes them indispensable in the development of innovative treatments.

Moreover, advancements in genetic engineering and protein expression technologies enable more efficient and precise manipulation of genetic material to produce desired proteins. The focus on accelerating the development of new therapeutic and diagnostic products will bolster the market outlook in the coming years.

The recombinant proteins industry is classified based on products & services, host cell, end-use, and region.

The yeast & fungi host-cell segment will grow rapidly through 2032. These microorganisms offer advantages such as rapid growth rates, high protein expression yields, and post-translational modification capabilities that are crucial for producing biologically active proteins. Yeast-based systems, including Saccharomyces cerevisiae and Pichia pastoris, are widely used for industrial-scale production due to their robustness and compatibility with complex protein structures. Fungi like Aspergillus niger and Trichoderma reesei are also gaining traction, particularly in enzyme production and industrial biotechnology applications.

The diagnostics segment will grow at a steady pace through 2032, as recombinant proteins are essential in diagnostic assays for detecting diseases and monitoring patient health. They are used to produce antigens, antibodies, and enzymes critical for diagnostic tests such as enzyme-linked immunosorbent assays (ELISA), lateral flow assays, and molecular diagnostics. The specificity, sensitivity, and reproducibility of recombinant proteins make them ideal for developing accurate and reliable diagnostic tools. As the global healthcare industry emphasizes early disease detection and personalized medicine, the demand for recombinant proteins in diagnostics is expected to grow.

Europe recombinant proteins industry will witness decent growth trends during 2024 and 2032, characterized by a strong biopharmaceutical sector, extensive research infrastructure, and supportive regulatory framework. Countries like Germany, Switzerland, and the United Kingdom are leading hubs for biotechnology and pharmaceutical research, driving demand for recombinant proteins in drug discovery and development. Moreover, stringent quality standards and favorable reimbursement policies for biopharmaceutical products contribute to market expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing demand for biopharmaceuticals and therapeutic proteins
  - 3.2.1.2 Advancements in protein engineering
  - 3.2.1.3 Growing prevalence of chronic and infectious diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High production costs
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Products & Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Products
- 5.2.1 Cytokines & growth factors
  - 5.2.1.1 Interferons (IFNs)
  - 5.2.1.2 Interleukins (ILs)
  - 5.2.1.3 Other cytokines & growth factors
- 5.2.2 Antibodies
- 5.2.3 Immune checkpoint proteins
- 5.2.4 Virus antigens
- 5.2.5 Enzymes
  - 5.2.5.1 Kinases
  - 5.2.5.2 Metabolic enzymes
  - 5.2.5.3 Other enzymes
- 5.2.6 Recombinant regulatory proteins
- 5.2.7 Hormones
- 5.2.8 Other products
5.3 Production services

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug discovery & development
- 6.2.1 Biologics
- 6.2.2 Vaccines
- 6.2.3 Cell & gene therapies
6.3 Research
6.4 Diagnostics
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Host-cell, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Mammalian systems
7.3 Insect cells
7.4 Yeast & fungi
7.5 Bacterial cells
7.6 Other host-cells

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical & biotechnology companies
8.3 Academic & research institutes
8.4 Contract research organizations (CRO's)
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa